Restarting teclistamab and talquetamab after prolonged dose delay may not require re–step-up dosing

Teclistamab and talquetamab are the first US Food and Drug Administration-approved B-cell maturation antigen CD3 and G protein-coupled receptor, family C, group 5, member D CD3 bispecific antibodies (bsAbs), respectively, for the treatment of triple-class-exposed patients with relapsed/ refractory multiple myeloma after 4 prior lines, based on the pivotal MajesTEC-1 and MonumenTAL-1 studies. 1,2Teclistamab and talquetamab are associated with unique adverse effects (AEs) including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).In MajesTEC-1, 72.1% of patients experienced CRS (most grade 1-2 with 1 grade 3 event). 1n the MonumenTAL-1 study, CRS occurred in 77% and 80% of patients who received weekly and biweekly dosing of talquetamab, respectively (most grade 1-2 except for 1 grade 3 event). 3To mitigate CRS and ICANS, the package insert recommends initiating therapy with step-up dosing (SUD), including premedication and inpatient monitoring during the SUD period.

Authors

Institutions

Publication Details

Journal
Blood Advances
Published
2025-03-06
DOI
https://doi.org/10.1182/bloodadvances.2024015344
Citations
4
Primary Topic
Health Systems, Economic Evaluations, Quality of Life
Type
article
Field-Weighted Citation Impact
12.52
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Restarting teclistamab and talquetamab after prolonged dose delay may not require re–step-up dosing

Heather Jolie Landau, Kylee H. Maclachlan, Hamza Hashmi, Issam S. Hamadeh et al.
4 citations
Blood Advances
Health Systems, Economic Evaluations, Quality of Life
12.52
article

Restarting teclistamab and talquetamab after prolonged dose delay may not require re–step-up dosing

Heather Jolie Landau, Kylee H. Maclachlan, Hamza Hashmi, Issam S. Hamadeh, Saad Z. Usmani, Tala Shekarkhand, Malin L. Hultcrantz, Gunjan L. Shah, Kevin C. Miller, Urvi Ashok Shah, Dhwani Patel, Alexander M. Lesokhin, Alice X. Wang, Michael Scordo, Eric Matthew Jurgens, Hani Hassoun, Sham Mailankody, Neha Korde, Sridevi Rajeeve, Sergio A. Giralt, David Nemirovsky, Andriy Derkach, Carlyn Rose C. Tan, Ross Firestone
article en
4 citations

Abstract

Teclistamab and talquetamab are the first US Food and Drug Administration-approved B-cell maturation antigen CD3 and G protein-coupled receptor, family C, group 5, member D CD3 bispecific antibodies (bsAbs), respectively, for the treatment of triple-class-exposed patients with relapsed/ refractory multiple myeloma after 4 prior lines, based on the pivotal MajesTEC-1 and MonumenTAL-1 studies. 1,2Teclistamab and talquetamab are associated with unique adverse effects (AEs) including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).In MajesTEC-1, 72.1% of patients experienced CRS (most grade 1-2 with 1 grade 3 event). 1n the MonumenTAL-1 study, CRS occurred in 77% and 80% of patients who received weekly and biweekly dosing of talquetamab, respectively (most grade 1-2 except for 1 grade 3 event). 3To mitigate CRS and ICANS, the package insert recommends initiating therapy with step-up dosing (SUD), including premedication and inpatient monitoring during the SUD period.

Blood AdvancesVol. 9(13)
Memorial Sloan Kettering Cancer Center (US)
Openalex Percentile: Top 2%
Health Systems, Economic Evaluations, Quality of Life
12.52
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.